1. Epigenetic regulation of PRAME in acute myeloid leukemia is different compared to CD34+ cells from healthy donors: effect of 5-AZA treatment.
- Author
-
Gutierrez-Cosío S, de la Rica L, Ballestar E, Santamaría C, Sánchez-Abarca LI, Caballero-Velazquez T, Blanco B, Calderón C, Herrero-Sánchez C, Carrancio S, Ciudad L, Cañizo C, San Miguel JF, and Pérez-Simón JA
- Subjects
- Antigens, Neoplasm metabolism, Antimetabolites, Antineoplastic pharmacology, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Blood Donors, Bone Marrow Cells drug effects, Bone Marrow Cells metabolism, Bone Marrow Cells pathology, Cells, Cultured, CpG Islands genetics, Cytogenetic Analysis, Epigenesis, Genetic drug effects, Epigenesis, Genetic physiology, Gene Expression Regulation, Leukemic drug effects, Health, Humans, Leukemia, Myeloid, Acute metabolism, Leukemia, Myeloid, Acute pathology, Stem Cells drug effects, Stem Cells physiology, Antigens, CD34 metabolism, Antigens, Neoplasm genetics, Azacitidine pharmacology, Leukemia, Myeloid, Acute genetics, Stem Cells metabolism
- Abstract
PRAME is a tumor associated antigen (TAA) of particular interest since it is widely expressed by lymphoid and myeloid malignancies. Several studies have associated high PRAME RNA levels with good prognosis in acute myeloid leukemia (AML). PRAME expression is regulated at the epigenetic level. For this reason inhibitors of DNA methylation, such as 5-azacytidine, can modulate the expression of this TAAs. In the current study we analyzed the effect of 5-azaC on the expression of PRAME in blasts versus CD34+ cells from healthy donors in an attempt to increase its expression, thus inducing a potential target for therapeutic strategies., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF